

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) may be approved if the following criteria are met:

- I. Individual is using for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema;

AND

- II. Individual is currently utilizing an inhaled corticosteroid (ICS)/long-acting beta-2 agonist (LABA) agent but requires additional treatment of airflow obstruction;

OR

- III. Individual is currently utilizing an inhaled corticosteroid (ICS)/long-acting beta-2 agonist (LABA) agent in combination with a long-acting muscarinic antagonist (LAMA) agent and Trelegy Ellipta will be replacing each agent.

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) may not be approved for the following:

- I. Individual with a hypersensitivity to milk proteins.

Note: The safety and efficacy of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) in the treatment of asthma has not been established. Trelegy Ellipta is not indicated for asthma or relief of acute bronchospasm

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability															
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed January 3, 2018.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. Available from: Available from: <http://goldcopd.org>. Accessed on: January 3, 2018.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.